	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	23/07/2025
	www.isa.gov.il			www.tase.co.il				Reference:	2025-02-054860	Time of broadcast: 14:03 14:03

Immediate Report

Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on

6K: Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

ea024982601-6k_purplebioEDGAR2_Bannerless_isa.pdf


References of previous documents relating to this matter(the reference does not constitute incorporation by reference):



Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 06/08/2024
Address: Oppenheimer, Science Park 4 , Rehovot 7670104 , Israel Tel: 03-9333121 , 03-9311321 Fax: 03-5097196
E-mail address: ir@purple-biotech.com Company site: www.kitovpharma.com

Previous names of reporting entity: KITOV PHARMA LTD, KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,

Name of the Signatory: Masas Ludmer Adi Position of Signatory in the reporting corporation: Company Controller Name of Employer Company:
Address: Menachem Begin Drive 132 , Tel Aviv 6701101 Telephone: 03-9333121 Facsimile: 03-5097196 E-mail: adim@kitovpharma.com 1
Israel